Has anyone ever actually been cured of or into remission cancer using Gerson Therapy?

All the research I can find says that the Gerson Institute never follows up any cases, yet claims lots of successes, and when clients were followed up, over 5 years, 20 of the 21 cases followed up were dead, and the remaining survivor still had cancer.
A friend of mine has embarked on using Gerson Therapy to treat her breast cancer (stage 1) and is not having any conventional treatment for it and I am terrified for her.

You are right to be frightened for her; with conventional medical treatment Stage 1 Breast Cancer has a near 100% 5 year survival rate. Your friend’s cancer will, if she pursues Gerson, be untreated and may spread and progress.

No, there is no evidence at all of Gerson treatment having effectively treated a single case of cancer.

It sounds as if you have read good information about this quack treatment; if you haven’t seen these, they may be useful. the first is about Gerson’s famous 50 ‘best cases’, only four of which appear anything like credible

http://www.users.on.net/~pmoran/cancer/Gerson.htm

http://www.quackwatch.org/01QuackeryRelatedTopics/OTA/ota03.html

I have actually tried this regime, briefly.

I was diagnosed with stage 3 grade 3 breast cancer almost 7 years ago. At the time I had been a vegan for 6 years (and a vegetarian for most of my life) and was a juicing enthusiast; I started most days with green juice. I mention this because an almost entirely vegan diet and frequent consumption of fresh juice is the basis of the diet Gerson followers claim will cure cancer.

I was also something of an alternative medicine enthusiast at the time, and frantic to avoid harsh treatments. I visited (among other alternative practitioners) a nutritionist, who guided me in starting a diet almost identical to to Gerson’s, recommended by a British nutrition organisation whose name I’ve forgotten .

I wasn’t willing to pay the few thousand pounds the organisation wanted for providing the information, visiting me and providing the food, vitamins etc I would need for two years, but the nutritionist agreed to give me the basic diet and guide me through it. I intended to follow it as a substitute for chemotherapy, and spent a couple of hundred pounds on vitamin pills and supplements. I passed on the enemas; the nutritionist was concerned thought this might be ok as I was taking milk thistle.

A couple of days into the regime, drinking juice every hour and consuming enormous amounts of vitamin pills caused me to vomit regularly, and in the end my stomach turned even as I contemplated the dreary routine of making and drinking the juices (it put me off juice for years). . There were nights when I went to bed weeping with hunger because I couldn’t face the bland and repetitive food I was ‘allowed’ on this restrictive (even for a vegan) diet. My weight plummeted and I felt very ill. I lasted two weeks and felt so much better when I started eating what the hell I wanted.

I’ve only known one person who followed the Gerson diet to the letter; she was a contributor to a breast cancer forums whose prognosis was almost as poor as mine. She was a fine, strong woman who had surgery but refused further conventional treatment.

She had a recurrence after a year or so; she continued with the Gerson diet and seemed to be doing well. A year or so later she stopped posting; I have no idea why, and it’s always a worry on a cancer forum when you stop hearing from someone suddenly. I emailed her and, very uncharacteristically, she didn’t email back. A website she ran on alternative Cancer Treatments came to a full stop too. I hope she’s still fit and well, but I fear the worst.

Yes, anecdote; but it’s impossible to provide anything else, either way, in the absence of proof.

I went on to have conventional treatment, and am fit and well and have been in remission for over 6 years.

I hope you may find some of this helpful to pass on to your friend

Interview w/ Dr. Contreras – Breast Cancer – Part 1

Living Proof $7.98 Inspiring drama tells the powerful true story of Dr. Dennis Slamon, a UCLA oncologist and researcher who was instrumental in the development of the breast cancer drug Herceptin. The film chronicles Dr. Slamon’s tireless efforts to get the drug approved, often at the expense of his personal life. Harry Connick, Jr., Amanda Bynes, Bernadette Peters, Amy Madigan, Regina King, Angie Harmon star. 91 mi…

Beating Cancer with Nutrition, book with CD $13.60 Beating Cancer with Nutrition. Sugar feeds Cancer: diet and supplements can starve tumors· Nutrition makes chemo and radiation more toxic to the tumor while protecting the patient. Nutrition changes underlying causes of cancer, improving outcome for cancer patients regardless of other therapies. Why Beating Cancer with Nutrition is unique: The book was developed after working with over 500 cancer…

Knockout: Interviews with Doctors Who Are Curing Cancer–And How to Prevent Getting It in the First Place $9.09 In Knockout, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments—treatments that build up the body rather than tear it down. Somers herself has stared cancer in the face, and a decade later she has conquered her fear and has emerged confident with the path she’s chosen.Now she shares her personal choices and outlines an array of options from doctors…

Breast Cancer Husband: How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond $3.95 A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time.When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give him …

Breast Cancer For Dummies $21.99 If you or someone you love has been diagnosed with breast cancer, you’re probably confused, afraid, shocked, or even angry. Or you may be all of the above. Let this book become your trusted manual. Discover more about the cancer, explore treatment options, find ways to make this part of your life easier. Let shared experiences serve as your knowledgeable guide and anchor to help you make wise and confident choices. Think of breast cancer as a journey and this book as your roadmap. Have you already been diagnosed? In that case, this book can help you explore these important truths: Breast cancer is not a death sentence. Most women diagnosed with early stage breast cancer can look forward to enjoying a healthy, full life. Not only are you unique as a person, but so, too, is your particular form of cancer, your treatment options, and your prognosis. Every day more is discovered about how to prevent, detect earlier, and more effectively treat breast cancer. You are not alone. More than two million women in the United States today are breast cancer survivors. Thousands of groups and programs across the country offer support, and chances are, one is close to your neighborhood. All the information in this book is based on the most recent research findings, the clinical expertise of oncologists, and the invaluable experiences of the women who have walked this road before. Breast Cancer For Dummies covers all of the following topics and more in simple, easy-to-understand terms: Coming to grips with breast cancer Decoding your pathology report Finding the right treatment for you Rekindling intimacy after treatment Health Insurance and money woes Talking to children about breast cancer This book can help you feel like you have a sister who’s a doctor, a sister who tells you what to expect every step of the way, who gives you the best advice she can, and guides you along the way. (Of course, there is absolutely no replacement for advice about you from your own doctor.) You’ll feel empowered to know and understand what’s going on in your body, so that you can become a part of your own treatment team and make decisions along with your doctors and your family.

Advances in Breast Cancer Management $139 Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development. Though novel therapeutic agents or "targeted therapy" hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have longrecognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this strategy and the results of the Oncotype DX Breast Cancer Assay, the first clinically available assay. In the last 5 years, the aromatase inhibitors have been investigated extensively as an alternative to tamoxifen or as a class of agents that adds to the effects of tamoxifen in postmenopausal woman with hormone receptor positive breast cancer. A review of the data from pivotal trials will be put in context by Dr O??? Regan. Similarly, adjuvant chemotherapy has been refined in recent years to include taxanes and trastuzamab in select patients. Dr. Ravdin will highlight the findings from the most recent (2005) Oxford Overview of randomized clinical trials involving chemotherapy and tamoxifen. Dr Hudis will provide a critical analysis of the how recent data related to the incorporation of taxanes and trastuzamab in adjuvant therapy programs refines clinical decision-making. Local therapy in the form of radiation and surgery are critical components of the management of breast cance

National Breast Cancer Coalition $89.22 Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. On September 20, 2010, the National Breast Cancer Coalition (NBCC), a grassroots advocacy organization that seeks to improve public policies surrounding breast cancer research, diagnosis and treatment, launched Breast Cancer Deadline 2020, a call to action for policymakers, researchers, breast cancer advocates and other stakeholders to eradicate the disease by January 1, 2020. NBCC has developed a strategic plan for meeting the deadline and is engaging scientists, researchers, providers, breast cancer advocates, and all stakeholders to ensure that we meet the deadline. Stakeholders are not limited to representatives of the scientific, regulatory and health care communities as well as industry, policy makers and advocates but also include others who are visionary, highrisk, highimpact leaders who can provide valuable outside perspectives. Author: Surhone, Lambert M./ Tennoe, Mariam T./ Henssonow, Susan F. Binding Type: Paperback Number of Pages: 112 Publication Date: 2011/05/21 Language: English Dimensions: 9.00 x 6.00 x 0.27 inches

Breast Cancer $79 Discusses key issues related to the screening, diagnosis and treatment of breast cancer by recognised international experts.

Angiotensin-(1-7): A Novel Small Molecule for the Targeted Treatment of Triple Negative Breast Cancer. $116.81 New – Triple negative breast cancer (TNBC), an aggressive breast tumor that disproportionately affects young and minority women, is associated with a poor survival rate regardless of stage at diagnosis due to development of distant metastases. Tumors from women with TNBC lack estrogen receptors and progesterone receptors and have basal expression of the human epidermal growth factor receptor 2 (HER2), severely limiting therapeutic strategies. The purpose of this study was to determine whether an

Angiotensin-(1-7): A novel small molecule for the targeted treatment of triple negative breast cancer. $49.99 Triple negative breast cancer (TNBC), an aggressive breast tumor that disproportionately affects young and minority women, is associated with a poor survival rate regardless of stage at diagnosis due to development of distant metastases. Tumors from women with TNBC lack estrogen receptors and progesterone receptors and have basal expression of the human epidermal growth factor receptor 2 (HER2), severely limiting therapeutic strategies. The purpose of this study was to determine whether angiotensin-(1-7) [Ang-(1-7)], an endogenous peptide hormone that activates the AT(1-7) receptor mas , inhibits the growth of triple negative breast cancer cells and tumors and identify the molecular mechanisms for the inhibition of cancer cell growth. Injection of MDA-MB-231 cells into the mammary fat pad of athymic mice resulted in triple negative breast tumors that were treated for 28 days with either saline or Ang-(1-7). The average tumor volume from mice treated with the heptapeptide was approximately 3-fold less than the size of tumors from control animals (170.8 +/- 21.4 mm3 vs. 546.7 +/- 87.9 mm3; n = 5, p < 0.05) and tumor weight was reduced from 1.0 +/- 0.2 g in the saline-treated mice to 0.5 +/- 0.1 g in Ang-(1-7)-treated mice (n = 5, p < 0.05). The reduced size of Ang-(1-7)-treated tumors was associated with low immunoreactivity to Ki67, a proliferation marker (84.2 +/- 8.2 compared to 41 +/- 7.6), suggesting that Ang-(1-7) attenuates cell growth. Activity of the MAP kinases ERK1 and ERK2 was reduced in tumors of Ang-(1-7)-treated mice which was associated with a receptor-mediated increase in the MAP kinase phosphatase DUSP1 (1.01 +/- 0.1 relative gene expression in tumors from saline-treated mice compared to 1.78 +/- 0.13 in tumors from Ang-(1-7)-treated mice). The decrease in tumor growth of Ang-(1-7)-treated mice was also associated with a reduction in the endothelial cell marker CD34 (a decrease in vessel density from 87.8 +/- 6.4 in tumors from saline-treated

Angiotensin-(1-7): A novel small molecule for the targeted treatment of triple negative breast cancer. $49.99 Triple negative breast cancer (TNBC), an aggressive breast tumor that disproportionately affects young and minority women, is associated with a poor survival rate regardless of stage at diagnosis due to development of distant metastases. Tumors from women with TNBC lack estrogen receptors and progesterone receptors and have basal expression of the human epidermal growth factor receptor 2 (HER2), severely limiting therapeutic strategies. The purpose of this study was to determine whether angiotensin-(1-7) [Ang-(1-7)], an endogenous peptide hormone that activates the AT(1-7) receptor mas , inhibits the growth of triple negative breast cancer cells and tumors and identify the molecular mechanisms for the inhibition of cancer cell growth. Injection of MDA-MB-231 cells into the mammary fat pad of athymic mice resulted in triple negative breast tumors that were treated for 28 days with either saline or Ang-(1-7). The average tumor volume from mice treated with the heptapeptide was approximately 3-fold less than the size of tumors from control animals (170.8 +/- 21.4 mm3 vs. 546.7 +/- 87.9 mm3; n = 5, p < 0.05) and tumor weight was reduced from 1.0 +/- 0.2 g in the saline-treated mice to 0.5 +/- 0.1 g in Ang-(1-7)-treated mice (n = 5, p < 0.05). The reduced size of Ang-(1-7)-treated tumors was associated with low immunoreactivity to Ki67, a proliferation marker (84.2 +/- 8.2 compared to 41 +/- 7.6), suggesting that Ang-(1-7) attenuates cell growth. Activity of the MAP kinases ERK1 and ERK2 was reduced in tumors of Ang-(1-7)-treated mice which was associated with a receptor-mediated increase in the MAP kinase phosphatase DUSP1 (1.01 +/- 0.1 relative gene expression in tumors from saline-treated mice compared to 1.78 +/- 0.13 in tumors from Ang-(1-7)-treated mice). The decrease in tumor growth of Ang-(1-7)-treated mice was also associated with a reduction in the endothelial cell marker CD34 (a decrease in vessel density from 87.8 +/- 6.4 in tumors from saline-treated

Breast Cancer – The Art and Science of Early Detection with Mammography: Perception, Interpretation, Histopathologic Correlation $195 Early detection is our most effective means for reducing the number of unnecessary deaths caused by breast cancer; however, the lack of skilled mammographic readings, especially in early stage breast cancer, makes this a less effective tool than it could be. In this book, one of the world’s most renowned mammographers shares his decades of experience in the analysis and interpretation of mammographic images.With Dr. Tabar’s clear procedures and expert guidance, you will learn to discern the most subtle of pathologic changes to ensure that patients receive optimal and timely treatment. You will also improve your ability to recognize the full range of normal anatomic variability, avoiding unnecessary additional imaging and interventional procedures.This book contains more than 1,600 high-definition images, many in full-color, to demonstrate anatomic structures, variations in normal tissue, and difficult-to-identify abnormalities. You will also appreciate clear photographs of pathologic specimens, including subgross 3-D, and large, thin-section histologic sections, correlated with mammographic images.The result of more than two decades of intensive clinical experience, this is the ultimate mammographic atlas for developing expert interpretive skills. No radiologist or breast imager should be without this highly instructive professional reference.